SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Novo Nordisk A/S Securities and Sets a Lead Plaintiff Deadline of September 30, 2025

Core Viewpoint - A class action lawsuit has been filed against Novo Nordisk A/S, alleging that the company made misleading statements regarding its growth potential and market conditions, leading to significant stock price declines following a lowered sales and profit outlook [1][4][5]. Group 1: Lawsuit Details - The class action lawsuit, Eric Barta v. Novo Nordisk A/S, was initiated in the United States District Court for the District of New Jersey for individuals who purchased Novo securities between May 7, 2025, and July 28, 2025 [1]. - The complaint claims that Novo Nordisk provided overly optimistic statements while concealing material adverse facts about its growth potential and market penetration capabilities [4]. Group 2: Financial Impact - On July 29, 2025, Novo Nordisk announced a reduction in its sales and profit outlook, attributing this to lower growth expectations for its products Wegovy and Ozempic, citing factors such as the persistent use of compounded GLP-1s and increased competition [5]. - Following this announcement, Novo's stock price plummeted from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025, marking a decline of approximately 21.83% in just one day [5].